Reuters logo
BRIEF-Sermonix Pharma secures worldwide rights to oral lasofoxifene from Ligand Pharma
February 28, 2017 / 2:00 PM / 7 months ago

BRIEF-Sermonix Pharma secures worldwide rights to oral lasofoxifene from Ligand Pharma

Feb 28 (Reuters) - Sermonix pharmaceuticals

* Sermonix Pharma says accord allows Sermonix to globally develop, commercialize drug for treatment of advanced breast cancer

* Sermonix Pharmaceuticals secures worldwide rights to oral lasofoxifene from ligand pharmaceuticals, expanding from U.S., Japan

* Sermonix Pharma-in near future,intend to move oral lasofoxifene into clinic in phase 2 trial for treating locally advanced,metastatic breast cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below